Last updated: October 27, 2026. This page is general information, not legal advice. See the note at the bottom. The short version In November 2025, Congress changed the federal legal definition of “hemp.” The change is in Section 781 of Public Law 119-37. The new definition counts total THC (including THCA), not only delta-9 THC. It also excludes certain hemp-derived cannabinoid products, including final products with more than 0.4 milligrams of total THC (plus similar-effect cannabinoids) per container. The law did not name CBD in these exclusions. It names THC, cannabinoids that cannot be made naturally by the plant, and cannabinoids with effects similar to THC. A September 2026 funding law (Public Law 119-103) moved most of the changes from November 12 to December 11, 2026. One part still starts November 12. The December 11 date is also the date that funding law runs out. Congress could still act before then. As of today, no change has passed. What the 2025 law changed Public Law 119-37 was signed on November 12, 2025. Section 781 rewrote the federal definition of hemp, effective 365 days after enactment (November 12, 2026). In the law’s text: Total THC. Hemp is the plant Cannabis sativa L. and its derivatives with a total tetrahydrocannabinols concentration, including THCA, of not more than 0.3 percent on a dry-weight basis. The 2018 definition used delta-9 THC only. Cannabinoids the plant cannot produce. Intermediate and final hemp-derived cannabinoid products containing cannabinoids “not capable of being naturally produced” by the plant are excluded from hemp. Cannabinoids made outside the plant. Products containing cannabinoids that the plant can produce but that were “synthesized or manufactured outside the plant” are also excluded. The container limit. Final hemp-derived cannabinoid products are excluded if they contain more than 0.4 milligrams combined total per container of total THC and other cannabinoids with similar effects (or marketed to have similar effects) as determined by the Secretary of Health and Human Services. Definition of “container.” The law defines it as the innermost wrapping, packaging or vessel in direct contact with the final product, enclosed for retail sale, such as a jar, bottle, bag, box, packet, can, carton or cartridge. The limit applies per container, not per serving. Industrial hemp. The definition expressly includes industrial hemp (fiber, stalk, grain, seed oil and other non-cannabinoid uses), and the cannabinoid-product provisions apply to products derived from hemp “other than industrial hemp.” The Congressional Research Service notes that products falling within these exclusions would no longer be treated as hemp and would instead be regulated under the Controlled Substances Act as marijuana. What the September 2026 law changed The Continuing Appropriations and Extensions Act, 2027 (H.R. 6500) became Public Law 119-103 on September 2, 2026. Its Section 2019 says that until December 11, 2026, the Section 781 amendments apply only to the products described in two provisions: intermediate and final products containing cannabinoids that are not capable of being naturally produced by the plant. That produces two dates: | Date | What applies, according to the law’s text and the Congressional Research Service | |—|—| | November 12, 2026 | Products containing cannabinoids not capable of being naturally produced by the plant are excluded from the hemp definition. | | December 11, 2026 | The rest of the new definition applies, including the total-THC standard, the exclusion for naturally producible cannabinoids made outside the plant, and the 0.4 mg per-container limit. | December 11, 2026 is also the date in H.R. 6500 when the continuing appropriations in that law expire. How the votes went August 8, 2026: the Senate voted 61–32 to table an amendment, offered by Sen. Ted Budd and others, that would have removed the delay. The Senate then passed H.R. 6500, 90–6, the same day (Senate roll call votes 227 and 228, as recorded on H.R. 6500 at Congress.gov and in GovInfo bill status data; KFF Health News summary of The Hill). September 1, 2026: the House agreed to the Senate amendment, 370–48 (House Clerk roll call 286). September 2, 2026: the President signed the bill as Public Law 119-103 (GovInfo bill status data for H.R. 6500; Public Law text). Where things stand as of October 27, 2026 Congress. The Congressional Research Service (update of September 28, 2026) lists introduced bills that would delay the new definition by two more years (H.R. 7024, H.R. 7010, S. 3686) or repeal it (H.R. 6209). The sources reviewed here did not report committee or floor votes on them. Lame-duck session. On October 26, 2026, Rep. Morgan Griffith (R-Va.) told reporters he wants his hemp regulation bill attached to a Republican reconciliation package before December 11 (Roll Call). The bill is H.R. 7212, the Hemp Enforcement, Modernization, and Protection Act, referred to the House Energy and Commerce Committee on January 22, 2026. As introduced, it would direct the FDA to set limits on intoxicating cannabinoid content in hemp-derived products within three years, with fallback limits of 5 mg per serving and 30 mg per package if it does not. It has not passed. FDA lists. Section 781 told the FDA to publish, within 90 days, lists of naturally producible cannabinoids, THC-class cannabinoids and similar-effect cannabinoids, plus more information about “container.” The Congressional Research Service said on September 28, 2026 that this had not been published. As of October 27, 2026, we did not find a later publication on FDA.gov or in the Federal Register. States. States set their own rules. Some states have set their own dates, according to their own agencies and statutes. Illinois: the Department of Revenue says that beginning November 12, 2026, consumable or topical products with more than 0.4 mg of total THC per container no longer meet the state’s hemp definition. Rhode Island: the Cannabis Control Commission says hemp-derived products above 0.4 mg of total THC per container offered for sale on or after December 11, 2026 will be noncompliant. Ohio: Revised Code 928.01, effective March 20, 2026, excludes final hemp-derived cannabinoid products above 0.4 mg combined
Introduction: A Shift in the Cannabis Conversation The world of cannabis and its derivatives is constantly evolving, driven by new research, changing perceptions, and significant policy shifts. Recently, a major development has captured headlines: the reclassification of cannabis to Schedule III by the U.S. Department of Justice. This move, while seemingly technical, carries profound implications that ripple through the entire industry, affecting everything from research to product availability. For many, the immediate question is: what does this mean for my beloved CBD routine? Will the Schedule III cannabis impact my access to CBD? Let’s delve into the nuances of this change and clarify its potential effects on your wellness journey. The Science Behind the Shift: Understanding Schedule III To truly grasp the significance of this reclassification, it’s essential to understand the Controlled Substances Act (CSA) and its scheduling system. Historically, cannabis has been classified as a Schedule I substance, alongside drugs like heroin, implying a high potential for abuse and no accepted medical use. This classification severely hampered research and created significant legal hurdles for the industry. The move to Schedule III, however, places cannabis in a category with substances like Tylenol with codeine, acknowledging its accepted medical uses and a moderate to low potential for physical and psychological dependence. This federal cannabis reform is a monumental step, opening doors for more extensive scientific inquiry and potentially streamlining regulatory pathways. The Schedule III cannabis impact on research alone is expected to be transformative, allowing scientists to explore the full therapeutic potential of cannabinoids without the restrictive barriers of a Schedule I classification. The Schedule III Cannabis Impact on CBD Products For consumers of hemp-derived CBD products, the immediate, practical Schedule III cannabis impact might seem less dramatic than the headlines suggest. The 2018 Farm Bill already legalized hemp—defined as cannabis with less than 0.3% Delta-9 THC—effectively separating CBD from marijuana in the eyes of federal law. Therefore, your access to high-quality CBD products, like those offered by Feel Good Edibles, remains secure. However, the broader Schedule III cannabis impact on the industry is undeniably positive. The rescheduling signals a shift towards a more rational, science-based approach to cannabis policy. This changing tide is likely to foster a more stable and mature market, encouraging further investment and innovation. As the stigma surrounding cannabis continues to dissipate, we can expect a greater emphasis on quality control, standardized testing, and transparent labeling—principles that have always been central to the Feel Good Edibles philosophy. What This Means for Your Wellness Routine If you’re currently enjoying the benefits of CBD, whether it’s for promoting overall well-being, you can continue your routine with confidence. The Schedule III cannabis impact does not threaten the legality or availability of hemp-derived CBD. Instead, it validates the growing recognition of cannabis’s therapeutic value. As the industry matures and research expands, you can anticipate an even wider array of targeted and effective CBD products. The focus will increasingly shift towards understanding the synergistic effects of different cannabinoids and terpenes, leading to more sophisticated formulations designed to address specific wellness needs. Benefits Beyond the Buzz: How Rescheduling Enhances Wellness The reclassification to Schedule III is not just a legal formality; it’s a catalyst for enhanced consumer confidence and product quality. With cannabis now recognized for its medical value, we can anticipate a surge in research and development. This will lead to a deeper understanding of cannabinoids, terpenes, and their synergistic effects, ultimately resulting in more targeted and effective products. The increased research will likely uncover new applications and refine existing ones. This commitment to science aligns perfectly with the values of Feel Good Edibles, where quality and efficacy are paramount. The Schedule III cannabis impact ultimately benefits the consumer by raising industry standards. Navigating Your Choices: The Feel Good Edibles Difference In this evolving landscape, choosing the right CBD products becomes even more crucial. While the Schedule III reclassification is a positive step, it doesn’t automatically guarantee the quality of every product on the market. Consumers must remain vigilant, prioritizing transparency, third-party testing, and reputable brands. Feel Good Edibles stands as a beacon of trust and quality. Our commitment to providing premium, lab-tested CBD products ensures that you receive the purest and most effective experience. Every Feel Good Edibles product is crafted with your well-being in mind. We believe in empowering you with natural solutions that enhance your life, and our dedication to excellence remains unwavering, regardless of federal classifications. Conclusion: A Brighter Future for CBD Wellness The Schedule III cannabis impact marks a significant turning point, signaling a more enlightened approach to cannabis policy. While the full ramifications will unfold over time, the immediate outlook for CBD users is overwhelmingly positive. Increased research, clearer regulations, and a more accepting public perception will undoubtedly lead to a richer, more diverse, and more effective range of CBD products. Feel Good Edibles remains at the forefront of this exciting journey, dedicated to delivering the highest quality CBD solutions to help you live a more balanced and fulfilling life. Embrace the future of wellness with confidence, knowing that your journey with Feel Good Edibles is supported by science, quality, and a commitment to your well-being.
Build a beginner-friendly CBD gummies routine with clearer product selection, practical timing, and better label awareness.
Discovery and Early Research Cannabinol was the first cannabinoid to be isolated from cannabis. British chemists Thomas B. Wood, W. T. N. Spivey, and Thomas Hill Easterfield isolated it in 1896. However, they were unable to determine its exact structure. In the 1930s, British chemist Robert Sidney Cahn was the first to accurately identify its chemical formula, and a decade later, in the 1940s, Roger Adams and his colleagues at the University of Illinois were the first to determine and synthesize the structure of CBN. For many years, scientists believed CBN was the primary psychoactive compound in cannabis. However, this theory was disproven in 1964 when Israeli chemist Raphael Mechoulam and his team at the Weizmann Institute of Science successfully isolated and synthesized delta-9-tetrahydrocannabinol (THC), the true psychoactive component responsible for the cannabis “high.” This pivotal discovery shifted the focus of cannabinoid research away from CBN. How Cannabinol is Formed Unlike other major cannabinoids like THC and cannabidiol (CBD), CBN is not produced directly by the cannabis plant. It is a byproduct of the degradation of THC that occurs over time with exposure to light and air. When THC molecules break down, they oxidize and convert into CBN. This is why CBN is found in higher concentrations in aged or poorly stored cannabis. Modern-Day Interest In the years following the discovery of THC, CBN was largely ignored by researchers. However, in recent years, renewed interest in the potential therapeutic benefits of all cannabinoids has brought CBN back into the spotlight. Preliminary studies and anecdotal evidence suggest that CBN may have a number of therapeutic properties. CBN is perhaps most known for its potential sedative effects, although this is still being studied. Some research indicates it may help with pain management. Like THC, CBN may act as an appetite stimulant. CBN may have anti-inflammatory properties, which could be beneficial for various conditions. While more research is needed to fully understand CBN’s effects and therapeutic potential, its unique history as the first isolated cannabinoid and its distinct formation process make it a fascinating subject in the world of cannabis science.
In the ever-evolving landscape of cannabis science and consumer understanding, a term that’s gaining increasing prominence is TAC, or Total Active Cannabinoids. While THC and CBD have long dominated the conversation, TAC offers a broader perspective on the chemical richness and potential effects of cannabis products. Understanding Total Active Cannabinoids requires a journey through the history of cannabinoid research, a clear definition of what it encompasses, and an appreciation for its significance in today’s cannabis market. The Historical Context: Beyond Single Molecules The early days of cannabis research largely focused on isolating and understanding individual cannabinoids, with THC taking center stage due to its psychoactive properties. Scientists diligently worked to identify, isolate, and characterize compounds like CBD, CBN, and CBG. This reductionist approach was crucial for understanding the fundamental effects of each molecule. However, as research progressed, a more holistic view began to emerge. The concept of the “entourage effect,” suggesting that the combined action of various cannabinoids and terpenes could produce effects greater than the sum of their individual parts, gained traction. This shift in perspective paved the way for the increasing relevance of metrics like Total Active Cannabinoids. Initially, cannabis testing often highlighted only the primary cannabinoids, particularly THC and sometimes CBD. However, as analytical techniques became more sophisticated and consumer awareness grew, the limitations of focusing solely on one or two compounds became apparent. Patients and recreational users alike began to seek a more comprehensive understanding of the chemical profile of their cannabis products. This demand for transparency and a more complete picture of the active components fueled the adoption of TAC as a valuable metric. Defining TAC: More Than Just THC So, what exactly is Total Active Cannabinoids? Simply put, TAC represents the total percentage by weight of all identified and quantified cannabinoids in a cannabis product that are considered “active.” This typically includes the major cannabinoids like THC (delta-9-THC and sometimes THCA, which can be converted to THC), CBD (CBD and sometimes CBDA), as well as other minor cannabinoids such as CBG, CBN, CBC, and THCV, among others. The specific list of cannabinoids included in the TAC calculation can sometimes vary slightly depending on the testing laboratory and regulatory requirements. It’s crucial to understand that TAC is not a single compound itself, but rather a summation of the concentrations of multiple individual cannabinoids. Think of it as a measure of the overall cannabinoid potency of a product. A high TAC value indicates that the product contains a significant amount of active cannabinoid compounds, regardless of the specific ratio of those compounds. The Significance of TAC in Today’s Cannabis Landscape The increasing emphasis on TAC reflects a growing understanding of the complex interplay of cannabinoids and their potential effects. TAC is becoming an increasingly important metric. With a more complete picture of potency, the THC percentage remains a key indicator of psychoactive potential. However, TAC offers a more holistic view of the overall potency and potential effects of a product. A product with a lower THC percentage but a high TAC might still contain significant amounts of other active cannabinoids working in concert. TAC acknowledges the potential synergy between different cannabinoids. By considering the total active cannabinoid content, consumers and researchers can better appreciate how the combined presence of various compounds might contribute to the overall experience. Moreover, providing TAC information empowers consumers to make more informed decisions. Individuals interested in minor cannabinoids like CBG or CBN can use the TAC value to gauge the overall presence of these compounds in a product. And, as the cannabis industry matures, standardized testing and labeling become increasingly important. TAC provides a valuable metric for quality control, ensuring that products consistently meet the cannabinoid content levels. For researchers, Total Active Cannabinoids offers a more comprehensive dataset for studying the effects of cannabis. Analyzing the total active cannabinoid profile, rather than focusing solely on THC or CBD, can lead to a deeper understanding of the complex pharmacology of cannabis. Navigating TAC on Product Labels When examining cannabis product labels, you’ll often find the THC and CBD percentages listed prominently. Increasingly, you’ll also see a TAC percentage. It’s important to understand how this number is derived. Typically, laboratory testing will quantify the individual cannabinoids present in a sample. The TAC is then calculated by summing the percentages of these identified active cannabinoids. It’s worth noting that some labs might also include precursor cannabinoids like THCA and CBDA in their TAC calculation, often after applying a conversion factor to estimate the amount of active THC and CBD that would be present after decarboxylation (the process of heating cannabis, which converts these precursors into their active forms). Understanding how a specific lab calculates TAC can provide further clarity when comparing different products. The Future of TAC: Embracing the Complexity As cannabis research continues to advance and consumer understanding deepens, the importance of TAC is likely to grow. It represents a move away from a singular focus on THC towards a more nuanced appreciation of the complex chemical composition of the cannabis plant. By considering the total active cannabinoid content, we gain a more comprehensive understanding of the potential effects and benefits of cannabis, paving the way for more informed choices, standardized quality control, and more insightful research into this multifaceted plant. TAC, therefore, is not just a number on a label; it’s a symbol of the evolving understanding and appreciation for the intricate world of cannabinoids.
